Days after posting positive data for the drug in head and neck cancer, ImClone Systems has suffered a setback after a late-stage trial of Erbitux in pancreatic cancer failed to meet its primary endpoint.
ImClone and partner Bristol-Myers Squibb announced that a Phase III study of Erbitux (cetuximab) plus a standard chemotherapy, Eli Lilly's Gemzar (gemcitabine) in patients with locally advanced unresectable or metastatic pancreatic cancer did not meet its primary endpoint of improving overall survival.
Hat tip: PharmaTimes
No comments:
Post a Comment